Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.

Agneskog E, Nowak P, Källander CF, Sönnerborg A.

J Med Virol. 2013 Apr;85(4):703-8. doi: 10.1002/jmv.23507. Epub 2013 Jan 30.

PMID:
23364785
[PubMed - indexed for MEDLINE]
2.

Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.

Reuman EC, Rhee SY, Holmes SP, Shafer RW.

J Antimicrob Chemother. 2010 Jul;65(7):1477-85. doi: 10.1093/jac/dkq140. Epub 2010 May 12.

PMID:
20462946
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.

Pereira-Vaz J, Duque V, Pereira B, Mota V, Morais C, Saraiva-da-Cunha J, Meliço-Silvestre A.

J Med Virol. 2012 Apr;84(4):551-4. doi: 10.1002/jmv.23232.

PMID:
22337292
[PubMed - indexed for MEDLINE]
4.

Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline.

Asahchop EL, Wainberg MA, Oliveira M, Xu H, Brenner BG, Moisi D, Ibanescu IR, Tremblay C.

AIDS. 2013 Mar 27;27(6):879-87. doi: 10.1097/QAD.0b013e32835d9f6d.

PMID:
23262501
[PubMed - indexed for MEDLINE]
5.

Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.

Varghese V, Shahriar R, Rhee SY, Liu T, Simen BB, Egholm M, Hanczaruk B, Blake LA, Gharizadeh B, Babrzadeh F, Bachmann MH, Fessel WJ, Shafer RW.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):309-15. doi: 10.1097/QAI.0b013e3181bca669.

PMID:
19734799
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.

Xu H, Quan Y, Brenner BG, Bar-Magen T, Oliveira M, Schader SM, Wainberg MA.

Antimicrob Agents Chemother. 2009 Nov;53(11):4667-72. doi: 10.1128/AAC.00800-09. Epub 2009 Aug 24.

PMID:
19704127
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.

Maïga AI, Descamps D, Morand-Joubert L, Malet I, Derache A, Cisse M, Koita V, Akonde A, Diarra B, Wirden M, Tounkara A, Verlinden Y, Katlama C, Costagliola D, Masquelier B, Calvez V, Marcelin AG.

Antimicrob Agents Chemother. 2010 Feb;54(2):728-33. doi: 10.1128/AAC.01335-09. Epub 2009 Dec 14.

PMID:
20008779
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.

Asahchop EL, Oliveira M, Wainberg MA, Brenner BG, Moisi D, Toni Td, Tremblay CL.

Antimicrob Agents Chemother. 2011 Feb;55(2):600-7. doi: 10.1128/AAC.01192-10. Epub 2010 Dec 6.

PMID:
21135184
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.

Llibre JM, Santos JR, Puig T, Moltó J, Ruiz L, Paredes R, Clotet B.

J Antimicrob Chemother. 2008 Nov;62(5):909-13. doi: 10.1093/jac/dkn297. Epub 2008 Jul 23.

PMID:
18653487
[PubMed - indexed for MEDLINE]
Free Article
10.

[Etravirine: genetic barrier and resistance development].

Llibre JM, Santos JR, Clotet B.

Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:32-9. doi: 10.1016/S0213-005X(09)73217-3. Review. Spanish.

PMID:
20116626
[PubMed - indexed for MEDLINE]
11.

Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma.

Vázquez-Rosales G, García Lerma JG, Yamamoto S, Switzer WM, Havlir D, Folks TM, Richman DD, Heneine W.

AIDS Res Hum Retroviruses. 1999 Sep 1;15(13):1191-200.

PMID:
10480632
[PubMed - indexed for MEDLINE]
12.

HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.

Aulicino PC, Rocco CA, Mecikovsky D, Bologna R, Mangano A, Sen L.

Antivir Ther. 2010;15(4):641-50. doi: 10.3851/IMP1571.

PMID:
20587857
[PubMed - indexed for MEDLINE]
13.

Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.

Wang J, Zhang G, Bambara RA, Li D, Liang H, Wu H, Smith HM, Lowe NR, Demeter LM, Dykes C.

J Virol. 2011 Oct;85(20):10861-73. doi: 10.1128/JVI.05116-11. Epub 2011 Aug 10.

PMID:
21835788
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.

Xu HT, Colby-Germinario SP, Asahchop EL, Oliveira M, McCallum M, Schader SM, Han Y, Quan Y, Sarafianos SG, Wainberg MA.

Antimicrob Agents Chemother. 2013 Jul;57(7):3100-9. doi: 10.1128/AAC.00348-13. Epub 2013 Apr 22.

PMID:
23612196
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.

Anta L, Llibre JM, Poveda E, Blanco JL, Alvarez M, Pérez-Elías MJ, Aguilera A, Caballero E, Soriano V, de Mendoza C; Resistance Platform of the Spanish AIDS Research Network.

AIDS. 2013 Jan 2;27(1):81-5. doi: 10.1097/QAD.0b013e3283584500.

PMID:
22842995
[PubMed - indexed for MEDLINE]
16.

Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing.

Hoffmann D, Garcia AD, Harrigan PR, Johnston IC, Nakasone T, García-Lerma JG, Heneine W.

PLoS One. 2011;6(7):e22019. doi: 10.1371/journal.pone.0022019. Epub 2011 Jul 20.

PMID:
21799767
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.

Gupta S, Vingerhoets J, Fransen S, Tambuyzer L, Azijn H, Frantzell A, Paredes R, Coakley E, Nijs S, Clotet B, Petropoulos CJ, Schapiro J, Huang W, Picchio G.

Antimicrob Agents Chemother. 2011 Jun;55(6):2872-9. doi: 10.1128/AAC.01695-10. Epub 2011 Apr 4.

PMID:
21464253
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

[Role of etravirine in combination antiretroviral therapy].

Domingo P.

Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:46-51. doi: 10.1016/S0213-005X(09)73219-7. Review. Spanish.

PMID:
20116628
[PubMed - indexed for MEDLINE]
19.

Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.

Nicot F, Saliou A, Raymond S, Sauné K, Dubois M, Massip P, Marchou B, Delobel P, Izopet J.

J Clin Virol. 2012 Oct;55(2):107-13. doi: 10.1016/j.jcv.2012.06.018. Epub 2012 Jul 20.

PMID:
22818969
[PubMed - indexed for MEDLINE]
20.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk